{"entity":{"id":"cancer-research-communications","kind":"journal","name":"Cancer research communications","aka":["Cancer Res Commun","Cancer Research Communications"],"tldr":"Cancer Research Communications is the AACR's fully open-access journal for rapid publication across all of cancer research, including confirmatory and null results. Read by researchers who want AACR peer review without a paywall.","summary":"Cancer Research Communications is an open access, peer-reviewed journal of the American Association for Cancer Research launched in October 2021 and published monthly since 2022. It covers the full spectrum of cancer research, aiming to accelerate discovery by rapidly publishing hypotheses, methods, results, data resources and new knowledge; articles may report novel findings, support previously published results or present thought-provoking null results. Its sections span molecular and cellular biology, tumour biology, immuno-oncology, emerging technologies and data science, therapeutic development, precision medicine and biomarkers, clinical research and trials, epidemiology and prevention, and health disparities. All content is free to read under the Budapest Open Access Initiative definition; DOAJ records the CC BY licence, an article processing charge with discounts, anonymous peer review and author retention of copyright. Indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://aacrjournals.org/cancerrescommun"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/489454"},{"label":"DOAJ record","url":"https://doaj.org/toc/2767-9764"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/cancerrescommun","issn":"2767-9764","scope":"cancer research","access":"open-access","founded":2021,"matchNames":["Cancer Res Commun","Cancer research communications","Cancer Research Communications"],"society":"American Association for Cancer Research"},"route":"/journals/cancer-research-communications/","neighbours":{"collection":[{"id":"pubmed-europepmc","kind":"collection","name":"PubMed & Europe PMC","route":"/collections/pubmed-europepmc/"}],"institution":[{"id":"aacr","kind":"institution","name":"American Association for Cancer Research (AACR)","route":"/institutions/aacr/"}],"paper":[{"id":"paper-nct05199272-cancer-res-commun-2025","kind":"paper","name":"First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies","route":"/key-papers/paper-nct05199272-cancer-res-commun-2025/"},{"id":"paper-cd47-colorectal-cancer-res-commun-2025","kind":"paper","name":"Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer","route":"/key-papers/paper-cd47-colorectal-cancer-res-commun-2025/"}],"journal":[{"id":"cancer-research","kind":"journal","name":"Cancer Research","route":"/journals/cancer-research/"}]}}